Ocugen (OCGN) said Thursday the Data and Safety Monitoring Board approved the continuation of its phase 1/2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration.
Initial phase 2 data showed OCU410 is safe and well-tolerated, with no serious adverse events reported, the company said.
Ocugen said dosing will conclude in early 2025, Ocugen said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments